momentum: momelotinib vs danazol in myelofibrosis
Published 3 years ago • 871 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
1:39
momentum: momelotinib vs danazol in r/r myelofibrosis
-
1:20
overview & updates on the momentum trial comparing momelotinib and danazol in myelofibrosis
-
1:04
long-term survival outcomes in pts with mf treated with momelotinib vs danazol in the momentum trial
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:20
momentum & the potential impact of approval of momelotinib in myelofibrosis
-
40:16
momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (momentum)
-
3:48
efficacy of momelotinib in thrombocytopenic patients with myelofibrosis from momentum
-
1:19:02
dr james liang - overview of mpns
-
7:39
how to use danazol - explain uses,side effects,interactions
-
1:24
updated results from the momentum study assessing the efficacy of momelotinib in mf
-
3:03
an insight into the momentum trial: safety and efficacy of momelotinib for the treatment of mf
-
2:48
updated results from the momentum trial
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
1:53
recent updates from the momentum trial and the value of momelotinib for the treatment of mf
-
1:40
momelotinib for the treatment of myelofibrosis
-
2:26
assessing the impact of momelotinib on transfusion burden in mf: analysis of simplify-1 & momentum
-
2:53
long-term safety of momelotinib in myelofibrosis: pooled data from three phase iii randomized trials
-
4:15
the latest data on momelotinib for mpns
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:21
clinical updates on the use of momelotinib for mpns
-
1:16
the rationale for combining magrolimab with ruxolitinib in myelofibrosis
-
2:03
prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy